Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer.

Zachary Quinn Benjamin E Leiby Guru P Sonpavde Atish D Choudhury Christopher J Sweeney David J Einstein Russell Zelig Szmulewitz A Oliver Sartor Beatrice Knudsen Eddy Shih-Hsin Yang William Kevin Kelly

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Combining niraparib with Radium-223 in patients with mCRPC was safe however further studies incorporating biomarkers will better elucidate the role of combinations of PARP inhibitors with DNA damaging and other agents.

Keyphrases

prostate cancer
squamous cell carcinoma
small cell lung cancer
dna damage
radical prostatectomy
circulating tumor
cell free
single molecule
dna repair
oxidative stress
replacement therapy
circulating tumor cells